Nektar Therapeutics Increase (Decrease) in Contract with Customer, Liability
Nektar Therapeutics (NKTR) reported Increase (Decrease) in Contract with Customer, Liability of -$1.06 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-02-28
- Nektar Therapeutics increase (decrease) in contract with customer, liability for the quarter ending 2021-12-31 was $0.00.
- Nektar Therapeutics increase (decrease) in contract with customer, liability for the quarter ending 2021-09-30 was $0.00.
- Nektar Therapeutics increase (decrease) in contract with customer, liability for the quarter ending 2021-06-30 was $0.00.
- Nektar Therapeutics increase (decrease) in contract with customer, liability for the quarter ending 2021-03-31 was -$605.00K.
- Nektar Therapeutics increase (decrease) in contract with customer, liability for fiscal 2022 was -$1.06M.
- Nektar Therapeutics increase (decrease) in contract with customer, liability for fiscal 2021 was -$605.00K.
- Nektar Therapeutics increase (decrease) in contract with customer, liability for fiscal 2020 was -$5.52M.
- Nektar Therapeutics increase (decrease) in contract with customer, liability for fiscal 2019 was -$16.57M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$1.06M 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | -$605.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | -$605.00K 10-Q · filed 2021-11-05 | -$1.05M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$605.00K 10-Q · filed 2021-08-06 | -$1.05M derived: sum of 3 quarters · filed 2023-02-28 | -$2.33M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$605.00K 10-Q · filed 2021-05-07 | -$1.05M derived: sum of 2 quarters · filed 2023-02-28 | -$2.33M derived: sum of 3 quarters · filed 2023-02-28 | -$3.61M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.73M derived: sum of 2 quarters · filed 2023-02-28 | -$3.01M derived: sum of 3 quarters · filed 2023-02-28 | -$5.52M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$2.56M derived: sum of 2 quarters · filed 2021-11-05 | -$5.07M 10-Q · filed 2021-11-05 | -$12.17M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$3.79M 10-Q · filed 2021-08-06 | -$10.89M derived: sum of 3 quarters · filed 2022-03-01 | -$13.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$2.51M 10-Q · filed 2021-05-07 | -$9.61M derived: sum of 2 quarters · filed 2022-03-01 | -$12.36M derived: sum of 3 quarters · filed 2022-03-01 | -$14.87M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$9.85M derived: sum of 2 quarters · filed 2022-03-01 | -$12.36M derived: sum of 3 quarters · filed 2022-03-01 | -$16.57M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$5.26M derived: sum of 2 quarters · filed 2020-11-06 | -$9.46M 10-Q · filed 2020-11-06 | -$13.87M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$6.71M 10-Q · filed 2020-08-07 | -$11.12M derived: sum of 3 quarters · filed 2021-02-26 | -$15.80M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$4.20M 10-Q · filed 2020-05-08 | -$8.60M derived: sum of 2 quarters · filed 2021-02-26 | -$13.29M derived: sum of 3 quarters · filed 2021-02-26 | -$15.86M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$9.08M derived: sum of 2 quarters · filed 2021-02-26 | -$11.65M derived: sum of 3 quarters · filed 2021-02-26 | -$15.33M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$4.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$7.25M derived: sum of 2 quarters · filed 2019-11-07 | -$10.93M 10-Q · filed 2019-11-07 | -$54.68M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | -$2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$6.25M 10-Q · filed 2019-08-09 | -$49.99M derived: sum of 3 quarters · filed 2020-02-28 | |
| 2018-03-31 | -$3.68M 10-Q · filed 2019-05-09 | -$47.42M derived: sum of 2 quarters · filed 2020-02-28 | ||
| 2017-12-31 | -$43.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$28.27M 10-K · filed 2020-02-28 | ||
| 2017-09-30 | $15.48M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | -$17.61M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |